Thomas Höger
Vorstandsvorsitzender bei Apogenix AG
Aktive Positionen von Thomas Höger
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Apogenix AG
 Apogenix AG BiotechnologyHealth Technology Apogenix AG develops immuno-oncology therapeutics for the treatment of cancer and malignant diseases. It offers protein-based therapeutics, including APG101, a human soluble fusion protein combining the extracellular domain of the CD95-receptor and the Fc part blocking CD95L-mediated signaling pathways; and IL-4 blocker that prevents over expression of anti-apoptotic proteins cells. The firm offers its drugs for malignant and inflammatory diseases. The company was founded by Peter Heinrich Krammer and Henning Walczak in 2005 and is headquartered in Heidelberg, Germany. | Vorstandsvorsitzender | 01.11.2005 | - |
Karriereverlauf von Thomas Höger
Ehemalige bekannte Positionen von Thomas Höger
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| DZ Bank AG (Securities) | Analyst-Equity | - | - |
| BASF SE | Corporate Officer/Principal | 01.01.1992 | - |
Knoll AG
 Knoll AG Pharmaceuticals: MajorHealth Technology Part of BASF SE, Knoll AG develops pharmaceuticals. The company is based in Haren, Germany. | Corporate Officer/Principal | - | - |
Statistik
International
| Deutschland | 5 |
Operativ
| Corporate Officer/Principal | 2 |
| Chief Executive Officer | 1 |
| Analyst-Equity | 1 |
Sektoral
| Health Technology | 3 |
| Finance | 2 |
| Producer Manufacturing | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| BASF SE | Producer Manufacturing |
| Private Unternehmen | 3 |
|---|---|
Apogenix AG
Apogenix AG BiotechnologyHealth Technology Apogenix AG develops immuno-oncology therapeutics for the treatment of cancer and malignant diseases. It offers protein-based therapeutics, including APG101, a human soluble fusion protein combining the extracellular domain of the CD95-receptor and the Fc part blocking CD95L-mediated signaling pathways; and IL-4 blocker that prevents over expression of anti-apoptotic proteins cells. The firm offers its drugs for malignant and inflammatory diseases. The company was founded by Peter Heinrich Krammer and Henning Walczak in 2005 and is headquartered in Heidelberg, Germany. | Health Technology |
Knoll AG
Knoll AG Pharmaceuticals: MajorHealth Technology Part of BASF SE, Knoll AG develops pharmaceuticals. The company is based in Haren, Germany. | Health Technology |
| DZ Bank AG (Securities) | Finance |
- Börse
- Insiders
- Thomas Höger
- Erfahrung